0001209191-23-041574.txt : 20230706
0001209191-23-041574.hdr.sgml : 20230706
20230706165301
ACCESSION NUMBER: 0001209191-23-041574
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230703
FILED AS OF DATE: 20230706
DATE AS OF CHANGE: 20230706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Skynner Michael
CENTRAL INDEX KEY: 0001776582
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 231074208
MAIL ADDRESS:
STREET 1: C/O BICYCLE THERAPEUTICS LIMITED
STREET 2: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB223AT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: BLOCKS A & B, PORTWAY BUILDING
STREET 2: GRANTA PARK, GREAT ABINGTON
CITY: CAMBRIDGE
STATE: X0
ZIP: CB21 6GS
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: BLOCKS A & B, PORTWAY BUILDING
STREET 2: GRANTA PARK, GREAT ABINGTON
CITY: CAMBRIDGE
STATE: X0
ZIP: CB21 6GS
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
DATE OF NAME CHANGE: 20181212
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-07-03
0
0001761612
BICYCLE THERAPEUTICS plc
BCYC
0001776582
Skynner Michael
C/O BICYCLE THERAPEUTICS PLC
BLOCKS A & B, PORTWAY BUILDING
CAMBRIDGE
X0
CB21 6GS
UNITED KINGDOM
0
1
0
0
Chief Technology Officer
0
Ordinary Shares
2023-07-03
4
S
0
451
25.10
D
70924
D
Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.85 to $25.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Kevin Lee, Attorney-in-Fact
2023-07-06